A

Apollomics Inc
NASDAQ:APLM

Watchlist Manager
Apollomics Inc
NASDAQ:APLM
Watchlist
Price: 16.725 USD 10.62%
Market Cap: 18.4m USD

Relative Value

There is not enough data to reliably calculate the relative value of APLM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APLM Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-39.9
Median 5Y
-126.3
Industry
24.1
vs History
vs Industry
Median 3Y
-40.4
Median 5Y
-127.8
Industry
21.8
vs History
vs Industry
Median 3Y
-37.2
Median 5Y
-117.8
Industry
23.8
vs History
vs Industry
Median 3Y
0.3
Median 5Y
0.9
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
46.6
Median 5Y
1.2
Industry
6.3
vs History
vs Industry
Median 3Y
46.6
Median 5Y
1.2
Industry
6.7
vs History
vs Industry
Median 3Y
89.7
Median 5Y
2.3
Industry
7.9
vs History
vs Industry
Median 3Y
89.7
Median 5Y
2.3
Industry
6.3
vs History
vs Industry
Median 3Y
97
Median 5Y
20.6
Industry
5.5

Multiples Across Competitors

APLM Competitors Multiples
Apollomics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Apollomics Inc
NASDAQ:APLM
18.4m USD 0 -22.4 55.8 55.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 861 489.7 -160 938.6 -195 430.8 -193 200.7
US
Abbvie Inc
NYSE:ABBV
400.4B USD 6.7 170.1 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
177.4B USD 4.9 25.3 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116B USD 9.9 31.5 23.2 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 080.5 -530.9 -578.1 -562.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD 5.7 17.8 17 19.3
AU
CSL Ltd
ASX:CSL
85.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.4B USD 16.6 1 225.7 161.1 195.4
NL
argenx SE
XBRU:ARGX
44.7B EUR 14.5 34.1 58.9 60.5
P/S Multiple
Revenue Growth P/S to Growth
US
A
Apollomics Inc
NASDAQ:APLM
Average P/S: 3 386 363.7
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 861 489.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 080.5
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.6
46%
0.4
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
P/E Multiple
Earnings Growth PEG
US
A
Apollomics Inc
NASDAQ:APLM
Average P/E: 192.8
Negative Multiple: -22.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 938.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
9%
2
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 225.7
N/A N/A
NL
argenx SE
XBRU:ARGX
34.1
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Apollomics Inc
NASDAQ:APLM
Average EV/EBITDA: 41.8
55.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.1
N/A N/A
NL
argenx SE
XBRU:ARGX
58.9
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Apollomics Inc
NASDAQ:APLM
Average EV/EBIT: 47.3
55.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 200.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195.4
N/A N/A
NL
argenx SE
XBRU:ARGX
60.5
N/A N/A